Esperion Therapeutics (NASDAQ:ESPR) Shares Gap Down – Time to Sell?

15 Jan 2026, 18:20 by Kim Johansen · The Markets Daily

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $3.23, but opened at $3.12. Esperion Therapeutics shares last traded at $3.0950, with a volume of 1,921,339 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on ESPR shares. Cantor Fitzgerald restated an “overweight” rating on shares of Esperion Therapeutics in a research note on Wednesday, November 12th. Citigroup restated a “market outperform” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. Piper Sandler assumed coverage on Esperion Therapeutics in a research note on Tuesday, November 25th. They set an “overweight” rating and a $9.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Esperion Therapeutics in a research note on Wednesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a report on Friday, September 19th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Esperion Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $7.20.

Get Our Latest Stock Analysis on Esperion Therapeutics

Esperion Therapeutics Stock Down 2.0%

The stock has a market capitalization of $756.62 million, a P/E ratio of -6.33, a PEG ratio of 10.11 and a beta of 1.04. The firm’s 50-day simple moving average is $3.56 and its 200 day simple moving average is $2.65.

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.07). The firm had revenue of $87.31 million for the quarter, compared to the consensus estimate of $78.33 million. As a group, equities analysts anticipate that Esperion Therapeutics, Inc. will post -0.29 EPS for the current fiscal year.

Insider Activity

In other news, CFO Benjamin Halladay sold 7,337 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $3.67, for a total transaction of $26,926.79. Following the completion of the sale, the chief financial officer owned 467,525 shares in the company, valued at approximately $1,715,816.75. This represents a 1.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.70% of the company’s stock.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. DHJJ Financial Advisors Ltd. lifted its position in shares of Esperion Therapeutics by 209.2% in the 3rd quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 6,380 shares in the last quarter. North Star Investment Management Corp. acquired a new position in Esperion Therapeutics in the 2nd quarter valued at approximately $25,000. Sivia Capital Partners LLC purchased a new stake in Esperion Therapeutics in the 2nd quarter worth approximately $25,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Esperion Therapeutics during the 3rd quarter valued at $29,000. Finally, R Squared Ltd purchased a new position in shares of Esperion Therapeutics during the 3rd quarter valued at $33,000. 47.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

(Get Free Report)

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.